Skip to main content
. 2018 Sep 19;9:940. doi: 10.3389/fphar.2018.00940

Table 4.

Mouse models (knockouts - KO or transgenic-TG, i.e., ubiquitous expression of the gene, unless specified) for intracrine enzymes.

Gene Modification MGI ID$ Phenotype
SatAR Null/KO1
MGI: 2388706
Endocrine (steroids) & reproductive endocrinology
- abnormal endocrine organs (adrenal, ovaries, prostate, testis).
- decreased steroids and increased adrenocorticotropin level.
- adrenocortical insufficiency.
- loss of negative feedback regulation at hypothalamic-pituitary levels.
Additional
Growth retardation neo/post natal lethality (incomplete penetrance). Reproductive system: abnormal uterus; incomplete spermatogenesis; abnormal genitalia.
CYP11A1 Null/KO2
MGI:5464022
Endocrine (steroids) and reproductive endocrinology
- abnormal adrenal gland morphology.
- increased circulating adrenocorticotropin level.
- lack of steroid production.
- decreased corticosterone and aldosterone levels.
Null/KO3
MGI: 2183813
Additional
Neonatal lethality (rescued by steroid supplementation); abnormal mitochondrion morphology; abnormal lipid level. Reproductive system: abnormal genitalia, prostate, testis morphology and spermatogenesis; Nervous system: abnormal adrenaline and noradrenaline level; abnormal food intake, hypoactivity; postnatal growth retardation.
CYP17A1 Null/KO4
MGI:3722780
Endocrine (steroids) & reproductive endocrinology
- increased circulating cholesterol level.
- decreased T level.
- early reproductive senescence.
Null/KO5
MGI:3047328

Null/KO
MGI:5605834
Additional
Homozygous embryonic lethality (Ed7, between implantation and somite formation). Reproductive system: abnormal sperm flagellum morphology/asthenozoospermia; reduced male fertility. Bone: abnormal bone structure, mineral content and density. Metabolism: increased total body fat; decreased lean body mass; increased circulating creatinine level; increased fasted circulating glucose level. Nervous system: abnormal sexual interaction.
CYP19A1 Null/KO6
MGI:2179439
Endocrine (steroids) and reproductive endocrinology
- increased circulating cholesterol, T, DHT, FSH, LH and prolactin.
- decreased circulating E2 level.
- abnormal endometrium (thin, decreased uterus weight).
- abnormal ovary (absence of follicles and corpus luteum, anovulation).
Null/KO7
MGI:2154536

Null/KO8
MGI:2389548
Additional
Reproductive system: ovary hemorrhage and cysts; increased seminal vesicle weight and abnormal seminiferous tubule epithelium and oligozoospermia; female infertility and reduced male fertility. Metabolism: increased fat; obesity and susceptibility to weight gain. Bone: decreased bone mineral density and bone mass; increased bone resorption, osteoclast cell number; abnormal compact and trabecular bone morphology. Metabolism: increased circulating glucose and triglyceride levels; impaired glucose tolerance; insulin resistance; hepatic steatosis; abnormal liver physiology. Nervous system: abnormal short term spatial reference memory; abnormal emotion/affect behavior; abnormal barbering behavior; increased grooming behavior; abnormal locomotor activation, bradykinesia; abnormal mating frequency.
17βHSD1 Null/KO9
MGI:5576042 and 3799948
Endocrine (steroids) & reproductive endocrinology
- abnormal corpus luteum morphology and decreased number.
- increased ovarian E1:E2 and A4:T ratios.
- increased LH level.
- reduced P level.
Additional
Increased circulating alkaline phosphatase level, pigmentation, abnormal retinal pigmentation, abnormal lens morphology, abnormal retina morphology, abnormal retinal pigmentation. Reproductive system: increased ovary weight; reduced female fertility. Metabolism: decreased circulating glucose level. Nervous system: abnormal behavior, response to light, sleep behavior, decreased exploration in new environment; abnormal motor coordination/balance.
17bHSD1 TG10 Reproductive endocrinology
- female have increased T levels.
- increased E1Inline graphicE2 conversion.
- masculinization in females.
- develop benign/malignant breast, ovarian and endometrial conditions.
17βHSD2 Null/KO11
MGI:3773836
No clear reproductive endocrinology phenotype
Additional
Heterozygous mice: growth retardation at birth ant postnatal; premature death; renal degeneration. Reproductive system: 70% embryonic lethality (Ed11.5) due to placental defects (homozygous); small and abnormal placenta morphology; Nervous system: brain phenotype with enlarged ventricles; abnormal cortex morphology; impaired balance, coordination, abnormal sleep pattern, megacephaly.
TG12 Reproductive endocrinology
- low T level.
Additional
Growth retardation; delayed eye opening; impaired retinoic signaling. Reproductive system: disrupted spermatogenesis. Bone: decreased bone formation (pre-pubertal age); decreased IGF-I and osteocalcin levels.
17βHSD4 Null/KO13 No clear reproductive endocrinology phenotype
Additional
Neonatal and postnatal lethality; postnatal growth retardation; abnormal mitochondrion morphology; abnormal bile salt level; hepatic steatosis. Reproductive system: abnormal testis and spermatid morphology; seminiferous tubule degeneration; small testis; abnormal gametogenesis; reduced male fertility. Nervous system: microgliosis; Purkinje cell degeneration; astrocytosis; axon degeneration; abnormal suckling behavior; increased anxiety-related response, tremors, ataxia, impaired coordination, hypoactivity, lethargy; abnormal gait. GIT: abnormal intestinal absorption. Metabolism: decreased body weight; abnormal lipid homeostasis and decreased fatty acid level.
17βHSD7 Null/KO14
MGI:3811923
Endocrine (steroids)
Cholesterol biosynthesis.
Null/KO15
MGI:4456868
Additional
Decreased embryo size; embryo lethality due to heart malformations (Ed10.5); abnormal blood vessel and capillary morphology. Nervous system: brain malformations; forebrain hypoplasia; increased neural tube apoptosis.
17βHSD9 Null/KO16
MGI: 2446073

Null/KO17
MGI:2388375
No clear reproductive endocrinology phenotype


Additional
Visual defects; abnormal eye electrophysiology, delayed dark adaptation.
17βHSD10 Null/KO18 No clear reproductive endocrinology phenotype
Additional
Mitochondria dysfunction; reduced plasma glucose and increase insulin levels. Nervous system: neuronal damage.
TG (brain specific)19 No clear reproductive endocrinology phenotype
Additional
Nervous system: Protect against ischemia, Parkinson, Alzheimer disease model
17βHSD11 Null/KO20
MGI:5581418
No clear reproductive endocrinology phenotype
Additional
Increased total circulating protein level. Nervous system: hyperactivity.
17βHSD12 Null/KO21 No clear reproductive endocrinology phenotype
Additional
Embryo lethality Ed 9.5; impaired organogenesis; reduced arachidonic acid synthesis. Reproductive system: ovarian dysfunction, fertility problems, smaller litters, significantly fewer numbers of ductal branches than wild type female mammary glands; ovulation problems. Nervous system: high embryo expression in neuronal structures.
17βHSD13 Null/KO22
MGI:5007180
No clear phenotype associated.
17βHSD14 Null/KO23
MGI:5007181
No clear reproductive endocrinology phenotype
Additional
Increased IgG2a level. Reproductive system: oligozoospermia, testis degeneration, male infertility. Nervous system: increased response to stress-induced hyperthermia.
17βHSD15 Null/KO24
MGI:3526658 &
3586379
No clear reproductive endocrinology phenotype
Additional
Abnormal eye electrophysiology, delayed dark adaptation
AKR1C3/ 17βHSD5* Null/KO25
MGI:3527218
Reproductive endocrinology
- long gestation, parturition failure.
- increased levels of P.
- prolonged estrous and diestrous.
Null/KO26
MGI:3774264
Additional
Small litter size, the number of pups, especially live pups, was markedly decreased hematopoietic system phenotype. Nervous system: Some behavioral phonotype,
SRD5A1 Null/KO27
MGI:1857454
Reproductive endocrinology
- parturition defects, rescued by 3α-DIOL supplementation.
Additional
Decreased litter size; small prostate.
SRD5A2 Null/KO28
MGI:2178039
Reproductive endocrinology
- T accumulation in reproductive tissues.
- impaired androgen-dependent gene expression.
- parturition defects, rescued by 3α-DIOL supplementation.
Additional
Decreased litter size; small prostate.
SRD5A3 Null/KO29
MGI:5520177
Mouse not thoroughly characterized
Embryonic lethality, abnormal heart morphology, abnormal neural tube closure
SULT1E1 Null/KO30
MGI:3529586
Reproductive endocrinology
- elevated circulating estrogen levels.
Additional
Disturbed platelet physiology. Reproductive system: leyding cell hyperplasia and abnormal morphology; abnormal testis morphology; abnormal placentation and amniotic fluid composition.
SULT2B1 Null/KO
MGI:5432568
(unpublished)
Endocrine (steroids)
disturbed cholesterol metabolism and levels.

No report/references was found for 17βHSD3, 17βHSD6, 17βHSD8, 3βHSD1, 3βHSD2, DHRS11, STS, SULT2A1, SULT1A1.

*

The human AKR1C3/17βHSD5 KO refers to mice with disrupted AKR1C18, however, functional conservation between the four human AKR1Cs and the eight mouse AKR1Cs in unclear (Sudeshna et al., 2013).

$

Reference ID refers to the Mouse Genome Informatics (MGI; www.informatics.jax.org. Accessed on date: February 2018) (Blake et al., 2017).

1

Caron et al. (1997), 2Huang et al. (2012), 3Hu et al. (2002), 4Liu et al. (2005), 5Bair and Mellon (2004), 6Nemoto et al. (2000), 7 Fisher et al. (1998), 8Honda et al. (1998), 9Hakkarainen et al. (2015), 10Saloniemi et al. (2010) and Järvensivu et al. (2018), 11Rantakari et al. (2008), 12Zhongyi et al. (2007), 13Baes et al. (2000), 14Shehu et al. (2008), 15Jokela et al. (2010), 16Shang et al. (2002), 17Driessen et al. (2000) and Sahu et al. (2015); 18Li et al. (2010) and Rauschenberger et al. (2010); 19Li et al. (2010); Rauschenberger et al. (2010), 20Dickinson et al. (2016), 21Rantakari et al. (2010); Kemilainen et al. (2016); 22Tang et al. (2010), 23Tang et al. (2010), 24Kim et al. (2005), 25Piekorz et al. (2005), 26Ishida et al. (2007), 27Mahendroo et al. (1996), 28Mahendroo et al. (2001), 29Dickinson et al. (2016), 30Qian et al. (2001) and Tong et al. (2005).